CEO Mark T Bertolini buys 1,000,000 shares of OSCR at $11.92, increasing stake 10.9%; stock down 42.3% from 52-week high.
Bertolini's purchase of 1,000,000 shares at $11.92 represents a material addition to his stake (10.9% increase from 9,196,876 to 10,196,876 shares), executed while OSCR trades 42.3% below its 52-week high of $22.47 and has declined 21.3% over the past 90 days. The company's fundamentals remain mixed: revenue reached $3.0B with strong 27.5% year-over-year growth, but Oscar Health remains unprofitable with net income of $-137.4M in the latest full fiscal year. The timing and scale of a CEO's open-market share purchase warrant investor attention given the stock's recent underperformance, though the purchase itself offers no direct insight into management's forward expectations without additional context about capital allocation strategy or stated rationale.